Properties (71)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:CytoSen_Therapeutics
|
| gptkbp:awards |
biotech innovation awards
|
| gptkbp:businessModel |
strategic alliances
development and commercialization |
| gptkbp:CEO |
gptkb:Arthur_L._L._de_Jong
|
| gptkbp:clinicalTrials |
gptkb:North_America
Europe positive outcomes published in peer-reviewed journals improved survival rates Phase 2 trials adaptive trial designs patient-centric approach Phase 1, Phase 2 international sites significant advancements in therapy. Kiadis_Pharma's_lead_product |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
patient support initiatives
|
| gptkbp:communityPartnerships |
global reach
|
| gptkbp:educationalPrograms |
cutting-edge research
|
| gptkbp:employees |
over 50
|
| gptkbp:financialPerformance |
publicly traded
|
| gptkbp:focus |
cell therapy
|
| gptkbp:founded |
2004
|
| gptkbp:funding |
venture capital
|
| gptkbp:future_plans |
innovative therapies
|
| gptkbp:futurePlans |
expand into new markets
|
| gptkbp:globalPresence |
international collaborations
|
| gptkbp:hasPopulation |
cancer patients
|
| gptkbp:hasPrograms |
experts in immunology
|
| gptkbp:headquarters |
gptkb:Amsterdam
|
| gptkbp:healthcare |
enhanced treatment options
|
| gptkbp:historicalResearch |
global partnerships
ongoing studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Kiadis Pharma
|
| gptkbp:impact |
personalized medicine
|
| gptkbp:investmentFocus |
annual reports
institutional investors series funding rounds |
| gptkbp:leadership |
experienced executives
|
| gptkbp:market |
hematological malignancies
leading biotechnology firm |
| gptkbp:marketSegment |
targeted therapies
|
| gptkbp:mission |
improve patient outcomes
|
| gptkbp:partnerships |
Sanofi
biopharmaceutical companies |
| gptkbp:products |
gptkb:Kiadis_T_cell_therapy
advanced therapies ATIR101 ATIR201 |
| gptkbp:regulatoryCompliance |
international standards
EMA_approval FDA_submissions |
| gptkbp:research |
grants and investments
|
| gptkbp:research_areas |
oncology
new treatment modalities |
| gptkbp:researchAreas |
cell-based therapies
|
| gptkbp:researchFocus |
immunotherapy
|
| gptkbp:researchInterest |
research findings
leading research institutions |
| gptkbp:socialResponsibility |
patient advocacy
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:targetMarket |
cancer treatment
|
| gptkbp:technology |
NK cell expansion technology
NK cell therapy |
| gptkbp:tradedOn |
Euronext Amsterdam
|
| gptkbp:tributaryOf |
multiple product candidates
|
| gptkbp:vision |
leading in cell therapy
|
| gptkbp:website |
www.kiadis.com
|